Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Chicago
University of Washington
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
Eli Lilly and Company